Oral SYK/JAK Inhibitor Gusacitinib for the Treatment of Chronic Hand Eczema: Results of a Randomized Phase 2 Study

By sjmartinez • April 25, 2023

Jimenez PA, Sofen HL, Bissonnette R, Lee M, Fowler J, Zammit DJ, Chen Y, Rao N, Denis L, Gupta S. Oral SYK/JAK Inhibitor Gusacitinib for the Treatment of Chronic Hand Eczema: Results of a Randomized Phase 2 Study. J Am Acad Dermatol. 2023 Apr 22:S0190-9622(23)00724-7. doi: 10.1016/j.jaad.2023.04.027. Epub ahead of print. PMID: 37094653.

Tags: Chronic Hand Eczema, Dermatology, Janase Kinase Inhibitor, modified Total Lesion Symptom Score, Olive View DoM, Physician Global Assessment, Publications, Spleen Kinase Inhibitor

Chilblain lupus erythematosus associated with erdafitinib therapy in a patient with metastatic bladder cancer

Truong A, Liu J, Ni C, Yashar S. Chilblain lupus erythematosus associated with erdafitinib therapy in a patient with metastatic bladder cancer. JAAD Case Rep.[...]

DNA-methylation age and accelerated epigenetic aging in blood as a tumor marker for predicting breast cancer susceptibility

Jung SY, Yu H, Deng Y, Pellegrini M. DNA-methylation age and accelerated epigenetic aging in blood as a tumor marker for predicting breast cancer susceptibility.[...]

Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 study

Tada Y, Armstrong AW, Imafuku S, Okubo Y, Morita A, Zhong Y, Zhuo J, Becker B, Napoli A, Banerjee S, Ohtsuki M. Deucravacitinib in Japanese[...]